MB
UTHR icon

MPM BioImpact’s United Therapeutics UTHR Stock Holding History

MPM BioImpact’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-58,907
Closed -$18.2M – 51
2025
Q1 		$18.2M Buy
58,907
+35,907
+156% +$12.3M 3.12% 12
2024
Q4 		$8.12M Buy
+23,000
New +$8.45M 1.15% 34

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

MPM BioImpact's UTHR Position: Q2 2025 in Review

MPM BioImpact sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 58,907 shares — an estimated $18.2M sold.

MPM BioImpact first reported a position in UTHR in Q4 2024 and held it in 2 quarters. The position peaked at $18.2M in Q1 2025. 671 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • MPM BioImpact reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
  • MPM BioImpact sold 58,907 United Therapeutics shares in Q2 2025, an estimated $18.2M.
  • MPM BioImpact first reported a position in United Therapeutics in Q4 2024 and held it in 2 quarters.
  • MPM BioImpact's United Therapeutics position peaked at $18.2M in Q1 2025.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on MPM BioImpact's 13F filing for Q2 2025, filed 14 Aug 2025.